Ruibo Li

Oct 22, 2024 | journals.plos.org | Ruibo Li |Sichuan province |Xi Chen |Yujie Wang

Loading metrics Open Access Peer-reviewedResearch Article Citation: Li R, Chen X, Wang Y (2024) Adverse events analysis of Relugolix (Orgovyx®) for prostate cancer based on the FDA Adverse Event Reporting System (FAERS). PLoS ONE 19(10): e0312481. https://doi.org/10.1371/journal.pone.0312481Editor: Kazunori Nagasaka, Teikyo University, School of Medicine, JAPANReceived: March 3, 2024; Accepted: October 7, 2024; Published: October 22, 2024Copyright: © 2024 Li et al.